Review



tocriscreen stem cell library  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Tocris tocriscreen stem cell library
    ( A ) Bar plot representing the distribution of targets for the 92 compounds included in the screen. ( B ) Schematic of the experimental design for the small molecule screen. ( C ) UMAP of the MG and MG-derived <t>cell</t> types. Cells are colored by cell type. ( D ) UMAP from C with cells colored by collection. ( E ) Dot plot of the genes used to define the MG-derived cell types from the screen. Dot size indicates the percent of cells that express the gene of interest. The color indicates the log10 mean UMIs per cell. ( F ) Quantification of the fold change in Neuron cell counts between each indicated condition and the Ascl1 only control. The plots from Collections 1 and 2 used only the control wells collected on their respective days. The dose of each compound is indicated by the size of the dot. ( G ) Quantification of the total cell counts for each treatment. The compound’s dose is indicated by the size of the dot. ( H ) Plots displaying the fold change of Neuron (red) and ProL (orange) cell counts compared to Ascl1 only across all doses for the top hits from the screen. All conditions in which at least 20 cells were recovered are displayed. Figure 2B is created with BioRender.com . Figure 2—source data 1. Small molecules used from <t>Tocriscreen</t> <t>Stem</t> Cell <t>Library.</t> Figure 2—source data 2. Genes used and GO annotations in unknown clusters.
    Tocriscreen Stem Cell Library, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tocriscreen stem cell library/product/Tocris
    Average 93 stars, based on 10 article reviews
    tocriscreen stem cell library - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "A multiplexed, single-cell sequencing screen identifies compounds that increase neurogenic reprogramming of murine Muller glia"

    Article Title: A multiplexed, single-cell sequencing screen identifies compounds that increase neurogenic reprogramming of murine Muller glia

    Journal: eLife

    doi: 10.7554/eLife.92091

    ( A ) Bar plot representing the distribution of targets for the 92 compounds included in the screen. ( B ) Schematic of the experimental design for the small molecule screen. ( C ) UMAP of the MG and MG-derived cell types. Cells are colored by cell type. ( D ) UMAP from C with cells colored by collection. ( E ) Dot plot of the genes used to define the MG-derived cell types from the screen. Dot size indicates the percent of cells that express the gene of interest. The color indicates the log10 mean UMIs per cell. ( F ) Quantification of the fold change in Neuron cell counts between each indicated condition and the Ascl1 only control. The plots from Collections 1 and 2 used only the control wells collected on their respective days. The dose of each compound is indicated by the size of the dot. ( G ) Quantification of the total cell counts for each treatment. The compound’s dose is indicated by the size of the dot. ( H ) Plots displaying the fold change of Neuron (red) and ProL (orange) cell counts compared to Ascl1 only across all doses for the top hits from the screen. All conditions in which at least 20 cells were recovered are displayed. Figure 2B is created with BioRender.com . Figure 2—source data 1. Small molecules used from Tocriscreen Stem Cell Library. Figure 2—source data 2. Genes used and GO annotations in unknown clusters.
    Figure Legend Snippet: ( A ) Bar plot representing the distribution of targets for the 92 compounds included in the screen. ( B ) Schematic of the experimental design for the small molecule screen. ( C ) UMAP of the MG and MG-derived cell types. Cells are colored by cell type. ( D ) UMAP from C with cells colored by collection. ( E ) Dot plot of the genes used to define the MG-derived cell types from the screen. Dot size indicates the percent of cells that express the gene of interest. The color indicates the log10 mean UMIs per cell. ( F ) Quantification of the fold change in Neuron cell counts between each indicated condition and the Ascl1 only control. The plots from Collections 1 and 2 used only the control wells collected on their respective days. The dose of each compound is indicated by the size of the dot. ( G ) Quantification of the total cell counts for each treatment. The compound’s dose is indicated by the size of the dot. ( H ) Plots displaying the fold change of Neuron (red) and ProL (orange) cell counts compared to Ascl1 only across all doses for the top hits from the screen. All conditions in which at least 20 cells were recovered are displayed. Figure 2B is created with BioRender.com . Figure 2—source data 1. Small molecules used from Tocriscreen Stem Cell Library. Figure 2—source data 2. Genes used and GO annotations in unknown clusters.

    Techniques Used: Derivative Assay, Control



    Similar Products

    93
    Tocris tocriscreen stem cell library
    ( A ) Bar plot representing the distribution of targets for the 92 compounds included in the screen. ( B ) Schematic of the experimental design for the small molecule screen. ( C ) UMAP of the MG and MG-derived <t>cell</t> types. Cells are colored by cell type. ( D ) UMAP from C with cells colored by collection. ( E ) Dot plot of the genes used to define the MG-derived cell types from the screen. Dot size indicates the percent of cells that express the gene of interest. The color indicates the log10 mean UMIs per cell. ( F ) Quantification of the fold change in Neuron cell counts between each indicated condition and the Ascl1 only control. The plots from Collections 1 and 2 used only the control wells collected on their respective days. The dose of each compound is indicated by the size of the dot. ( G ) Quantification of the total cell counts for each treatment. The compound’s dose is indicated by the size of the dot. ( H ) Plots displaying the fold change of Neuron (red) and ProL (orange) cell counts compared to Ascl1 only across all doses for the top hits from the screen. All conditions in which at least 20 cells were recovered are displayed. Figure 2B is created with BioRender.com . Figure 2—source data 1. Small molecules used from <t>Tocriscreen</t> <t>Stem</t> Cell <t>Library.</t> Figure 2—source data 2. Genes used and GO annotations in unknown clusters.
    Tocriscreen Stem Cell Library, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tocriscreen stem cell library/product/Tocris
    Average 93 stars, based on 1 article reviews
    tocriscreen stem cell library - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    90
    Tocris small molecules from the tocriscreen stem cell library
    ( A ) Bar plot representing the distribution of targets for the 92 compounds included in the screen. ( B ) Schematic of the experimental design for the small molecule screen. ( C ) UMAP of the MG and MG-derived <t>cell</t> types. Cells are colored by cell type. ( D ) UMAP from C with cells colored by collection. ( E ) Dot plot of the genes used to define the MG-derived cell types from the screen. Dot size indicates the percent of cells that express the gene of interest. The color indicates the log10 mean UMIs per cell. ( F ) Quantification of the fold change in Neuron cell counts between each indicated condition and the Ascl1 only control. The plots from Collections 1 and 2 used only the control wells collected on their respective days. The dose of each compound is indicated by the size of the dot. ( G ) Quantification of the total cell counts for each treatment. The compound’s dose is indicated by the size of the dot. ( H ) Plots displaying the fold change of Neuron (red) and ProL (orange) cell counts compared to Ascl1 only across all doses for the top hits from the screen. All conditions in which at least 20 cells were recovered are displayed. Figure 2B is created with BioRender.com . Figure 2—source data 1. Small molecules used from <t>Tocriscreen</t> <t>Stem</t> Cell <t>Library.</t> Figure 2—source data 2. Genes used and GO annotations in unknown clusters.
    Small Molecules From The Tocriscreen Stem Cell Library, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/small molecules from the tocriscreen stem cell library/product/Tocris
    Average 90 stars, based on 1 article reviews
    small molecules from the tocriscreen stem cell library - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Tocris small molecules tocriscreen stem cell library
    ( A ) Bar plot representing the distribution of targets for the 92 compounds included in the screen. ( B ) Schematic of the experimental design for the small molecule screen. ( C ) UMAP of the MG and MG-derived <t>cell</t> types. Cells are colored by cell type. ( D ) UMAP from C with cells colored by collection. ( E ) Dot plot of the genes used to define the MG-derived cell types from the screen. Dot size indicates the percent of cells that express the gene of interest. The color indicates the log10 mean UMIs per cell. ( F ) Quantification of the fold change in Neuron cell counts between each indicated condition and the Ascl1 only control. The plots from Collections 1 and 2 used only the control wells collected on their respective days. The dose of each compound is indicated by the size of the dot. ( G ) Quantification of the total cell counts for each treatment. The compound’s dose is indicated by the size of the dot. ( H ) Plots displaying the fold change of Neuron (red) and ProL (orange) cell counts compared to Ascl1 only across all doses for the top hits from the screen. All conditions in which at least 20 cells were recovered are displayed. Figure 2B is created with BioRender.com . Figure 2—source data 1. Small molecules used from <t>Tocriscreen</t> <t>Stem</t> Cell <t>Library.</t> Figure 2—source data 2. Genes used and GO annotations in unknown clusters.
    Small Molecules Tocriscreen Stem Cell Library, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/small molecules tocriscreen stem cell library/product/Tocris
    Average 90 stars, based on 1 article reviews
    small molecules tocriscreen stem cell library - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Tocris small molecule library screening tocriscreen stem cell toolbox
    ( A ) Bar plot representing the distribution of targets for the 92 compounds included in the screen. ( B ) Schematic of the experimental design for the small molecule screen. ( C ) UMAP of the MG and MG-derived <t>cell</t> types. Cells are colored by cell type. ( D ) UMAP from C with cells colored by collection. ( E ) Dot plot of the genes used to define the MG-derived cell types from the screen. Dot size indicates the percent of cells that express the gene of interest. The color indicates the log10 mean UMIs per cell. ( F ) Quantification of the fold change in Neuron cell counts between each indicated condition and the Ascl1 only control. The plots from Collections 1 and 2 used only the control wells collected on their respective days. The dose of each compound is indicated by the size of the dot. ( G ) Quantification of the total cell counts for each treatment. The compound’s dose is indicated by the size of the dot. ( H ) Plots displaying the fold change of Neuron (red) and ProL (orange) cell counts compared to Ascl1 only across all doses for the top hits from the screen. All conditions in which at least 20 cells were recovered are displayed. Figure 2B is created with BioRender.com . Figure 2—source data 1. Small molecules used from <t>Tocriscreen</t> <t>Stem</t> Cell <t>Library.</t> Figure 2—source data 2. Genes used and GO annotations in unknown clusters.
    Small Molecule Library Screening Tocriscreen Stem Cell Toolbox, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/small molecule library screening tocriscreen stem cell toolbox/product/Tocris
    Average 90 stars, based on 1 article reviews
    small molecule library screening tocriscreen stem cell toolbox - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    93
    Tocris tocriscreen stem cell toolbox kit
    ( A ) Bar graph shows expression profile of MYH isoforms in hiPSC-1-derived myotubes. Data are shown as mean ± S.E.M.; n = 3, ***p<0.001. ( B ) Bar graph shows the ratio of % MyHC-stained area to % DAPI area in myotubes resulting from treatment with five candidates identified by the small molecule screening. Data show significant increase (***p<0.001) compared to DMSO in all three PS cell lines analyzed (hESC-1, hiPSC-1 and hiPSC-2). Data from three independent replicates are shown, normalized to DMSO, as mean ± S.E.M. ( C ) Bar graph shows the ratio of % MyHC-stained area to % DAPI area in iPS cell-derived myotubes that had been differentiated in the presence of all candidates combined, or with individual candidates excluded from the overall combination. Data from three independent replicates are shown normalized to DMSO. Values are shown as mean ± S.E.M. ***p<0.001. ( D ) Representative images show immunostaining for MyHC (in red) in hiPSC-1 myotubes differentiated with combinatory treatments of small molecules or DMSO. DAPI stains nuclei (in blue). Scale bar is 100 μm. ( E ) Bar graph shows fusion index analysis of myotubes that were differentiated with small molecule combinations or DMSO. Data are shown as mean of three independent replicates ± S.E.M. ***p<0.001. ( F ) Stacked bar graph shows the frequency of number of nuclei per myotube upon differentiation with combinatory treatments or DMSO. Data are shown as mean of three independent replicates ± S.E.M. Statistical analysis compares each combination to DMSO. *p<0.05 **p<0.01 ***p<0.001. 10.7554/eLife.47970.006 Figure 1—source data 1. <t>Tocriscreen</t> Stem Cell Toolbox compounds tested during myogenic terminal differentiation of PS cell lines.
    Tocriscreen Stem Cell Toolbox Kit, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tocriscreen stem cell toolbox kit/product/Tocris
    Average 93 stars, based on 1 article reviews
    tocriscreen stem cell toolbox kit - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    90
    Tocris small molecule library screening tocriscreen stem cell toolbox kit
    ( A ) Bar graph shows expression profile of MYH isoforms in hiPSC-1-derived myotubes. Data are shown as mean ± S.E.M.; n = 3, ***p<0.001. ( B ) Bar graph shows the ratio of % MyHC-stained area to % DAPI area in myotubes resulting from treatment with five candidates identified by the small molecule screening. Data show significant increase (***p<0.001) compared to DMSO in all three PS cell lines analyzed (hESC-1, hiPSC-1 and hiPSC-2). Data from three independent replicates are shown, normalized to DMSO, as mean ± S.E.M. ( C ) Bar graph shows the ratio of % MyHC-stained area to % DAPI area in iPS cell-derived myotubes that had been differentiated in the presence of all candidates combined, or with individual candidates excluded from the overall combination. Data from three independent replicates are shown normalized to DMSO. Values are shown as mean ± S.E.M. ***p<0.001. ( D ) Representative images show immunostaining for MyHC (in red) in hiPSC-1 myotubes differentiated with combinatory treatments of small molecules or DMSO. DAPI stains nuclei (in blue). Scale bar is 100 μm. ( E ) Bar graph shows fusion index analysis of myotubes that were differentiated with small molecule combinations or DMSO. Data are shown as mean of three independent replicates ± S.E.M. ***p<0.001. ( F ) Stacked bar graph shows the frequency of number of nuclei per myotube upon differentiation with combinatory treatments or DMSO. Data are shown as mean of three independent replicates ± S.E.M. Statistical analysis compares each combination to DMSO. *p<0.05 **p<0.01 ***p<0.001. 10.7554/eLife.47970.006 Figure 1—source data 1. <t>Tocriscreen</t> Stem Cell Toolbox compounds tested during myogenic terminal differentiation of PS cell lines.
    Small Molecule Library Screening Tocriscreen Stem Cell Toolbox Kit, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/small molecule library screening tocriscreen stem cell toolbox kit/product/Tocris
    Average 90 stars, based on 1 article reviews
    small molecule library screening tocriscreen stem cell toolbox kit - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    93
    Tocris tocriscreen stem cell toolbox
    ( A ) Bar graph shows expression profile of MYH isoforms in hiPSC-1-derived myotubes. Data are shown as mean ± S.E.M.; n = 3, ***p<0.001. ( B ) Bar graph shows the ratio of % MyHC-stained area to % DAPI area in myotubes resulting from treatment with five candidates identified by the small molecule screening. Data show significant increase (***p<0.001) compared to DMSO in all three PS cell lines analyzed (hESC-1, hiPSC-1 and hiPSC-2). Data from three independent replicates are shown, normalized to DMSO, as mean ± S.E.M. ( C ) Bar graph shows the ratio of % MyHC-stained area to % DAPI area in iPS cell-derived myotubes that had been differentiated in the presence of all candidates combined, or with individual candidates excluded from the overall combination. Data from three independent replicates are shown normalized to DMSO. Values are shown as mean ± S.E.M. ***p<0.001. ( D ) Representative images show immunostaining for MyHC (in red) in hiPSC-1 myotubes differentiated with combinatory treatments of small molecules or DMSO. DAPI stains nuclei (in blue). Scale bar is 100 μm. ( E ) Bar graph shows fusion index analysis of myotubes that were differentiated with small molecule combinations or DMSO. Data are shown as mean of three independent replicates ± S.E.M. ***p<0.001. ( F ) Stacked bar graph shows the frequency of number of nuclei per myotube upon differentiation with combinatory treatments or DMSO. Data are shown as mean of three independent replicates ± S.E.M. Statistical analysis compares each combination to DMSO. *p<0.05 **p<0.01 ***p<0.001. 10.7554/eLife.47970.006 Figure 1—source data 1. <t>Tocriscreen</t> Stem Cell Toolbox compounds tested during myogenic terminal differentiation of PS cell lines.
    Tocriscreen Stem Cell Toolbox, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tocriscreen stem cell toolbox/product/Tocris
    Average 93 stars, based on 1 article reviews
    tocriscreen stem cell toolbox - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) Bar plot representing the distribution of targets for the 92 compounds included in the screen. ( B ) Schematic of the experimental design for the small molecule screen. ( C ) UMAP of the MG and MG-derived cell types. Cells are colored by cell type. ( D ) UMAP from C with cells colored by collection. ( E ) Dot plot of the genes used to define the MG-derived cell types from the screen. Dot size indicates the percent of cells that express the gene of interest. The color indicates the log10 mean UMIs per cell. ( F ) Quantification of the fold change in Neuron cell counts between each indicated condition and the Ascl1 only control. The plots from Collections 1 and 2 used only the control wells collected on their respective days. The dose of each compound is indicated by the size of the dot. ( G ) Quantification of the total cell counts for each treatment. The compound’s dose is indicated by the size of the dot. ( H ) Plots displaying the fold change of Neuron (red) and ProL (orange) cell counts compared to Ascl1 only across all doses for the top hits from the screen. All conditions in which at least 20 cells were recovered are displayed. Figure 2B is created with BioRender.com . Figure 2—source data 1. Small molecules used from Tocriscreen Stem Cell Library. Figure 2—source data 2. Genes used and GO annotations in unknown clusters.

    Journal: eLife

    Article Title: A multiplexed, single-cell sequencing screen identifies compounds that increase neurogenic reprogramming of murine Muller glia

    doi: 10.7554/eLife.92091

    Figure Lengend Snippet: ( A ) Bar plot representing the distribution of targets for the 92 compounds included in the screen. ( B ) Schematic of the experimental design for the small molecule screen. ( C ) UMAP of the MG and MG-derived cell types. Cells are colored by cell type. ( D ) UMAP from C with cells colored by collection. ( E ) Dot plot of the genes used to define the MG-derived cell types from the screen. Dot size indicates the percent of cells that express the gene of interest. The color indicates the log10 mean UMIs per cell. ( F ) Quantification of the fold change in Neuron cell counts between each indicated condition and the Ascl1 only control. The plots from Collections 1 and 2 used only the control wells collected on their respective days. The dose of each compound is indicated by the size of the dot. ( G ) Quantification of the total cell counts for each treatment. The compound’s dose is indicated by the size of the dot. ( H ) Plots displaying the fold change of Neuron (red) and ProL (orange) cell counts compared to Ascl1 only across all doses for the top hits from the screen. All conditions in which at least 20 cells were recovered are displayed. Figure 2B is created with BioRender.com . Figure 2—source data 1. Small molecules used from Tocriscreen Stem Cell Library. Figure 2—source data 2. Genes used and GO annotations in unknown clusters.

    Article Snippet: Drugs used were all from the Tocriscreen Stem Cell Library (Tocris, 7340) and were administered in 1 μl of dimethyl sulfoxide (DMSO) at 10 mM.

    Techniques: Derivative Assay, Control

    ( A ) Bar graph shows expression profile of MYH isoforms in hiPSC-1-derived myotubes. Data are shown as mean ± S.E.M.; n = 3, ***p<0.001. ( B ) Bar graph shows the ratio of % MyHC-stained area to % DAPI area in myotubes resulting from treatment with five candidates identified by the small molecule screening. Data show significant increase (***p<0.001) compared to DMSO in all three PS cell lines analyzed (hESC-1, hiPSC-1 and hiPSC-2). Data from three independent replicates are shown, normalized to DMSO, as mean ± S.E.M. ( C ) Bar graph shows the ratio of % MyHC-stained area to % DAPI area in iPS cell-derived myotubes that had been differentiated in the presence of all candidates combined, or with individual candidates excluded from the overall combination. Data from three independent replicates are shown normalized to DMSO. Values are shown as mean ± S.E.M. ***p<0.001. ( D ) Representative images show immunostaining for MyHC (in red) in hiPSC-1 myotubes differentiated with combinatory treatments of small molecules or DMSO. DAPI stains nuclei (in blue). Scale bar is 100 μm. ( E ) Bar graph shows fusion index analysis of myotubes that were differentiated with small molecule combinations or DMSO. Data are shown as mean of three independent replicates ± S.E.M. ***p<0.001. ( F ) Stacked bar graph shows the frequency of number of nuclei per myotube upon differentiation with combinatory treatments or DMSO. Data are shown as mean of three independent replicates ± S.E.M. Statistical analysis compares each combination to DMSO. *p<0.05 **p<0.01 ***p<0.001. 10.7554/eLife.47970.006 Figure 1—source data 1. Tocriscreen Stem Cell Toolbox compounds tested during myogenic terminal differentiation of PS cell lines.

    Journal: eLife

    Article Title: Screening identifies small molecules that enhance the maturation of human pluripotent stem cell-derived myotubes

    doi: 10.7554/eLife.47970

    Figure Lengend Snippet: ( A ) Bar graph shows expression profile of MYH isoforms in hiPSC-1-derived myotubes. Data are shown as mean ± S.E.M.; n = 3, ***p<0.001. ( B ) Bar graph shows the ratio of % MyHC-stained area to % DAPI area in myotubes resulting from treatment with five candidates identified by the small molecule screening. Data show significant increase (***p<0.001) compared to DMSO in all three PS cell lines analyzed (hESC-1, hiPSC-1 and hiPSC-2). Data from three independent replicates are shown, normalized to DMSO, as mean ± S.E.M. ( C ) Bar graph shows the ratio of % MyHC-stained area to % DAPI area in iPS cell-derived myotubes that had been differentiated in the presence of all candidates combined, or with individual candidates excluded from the overall combination. Data from three independent replicates are shown normalized to DMSO. Values are shown as mean ± S.E.M. ***p<0.001. ( D ) Representative images show immunostaining for MyHC (in red) in hiPSC-1 myotubes differentiated with combinatory treatments of small molecules or DMSO. DAPI stains nuclei (in blue). Scale bar is 100 μm. ( E ) Bar graph shows fusion index analysis of myotubes that were differentiated with small molecule combinations or DMSO. Data are shown as mean of three independent replicates ± S.E.M. ***p<0.001. ( F ) Stacked bar graph shows the frequency of number of nuclei per myotube upon differentiation with combinatory treatments or DMSO. Data are shown as mean of three independent replicates ± S.E.M. Statistical analysis compares each combination to DMSO. *p<0.05 **p<0.01 ***p<0.001. 10.7554/eLife.47970.006 Figure 1—source data 1. Tocriscreen Stem Cell Toolbox compounds tested during myogenic terminal differentiation of PS cell lines.

    Article Snippet: To determine whether small molecule compounds may enhance the maturation of PS cell-derived myotubes, we performed a small molecule library screening using the Tocriscreen stem cell toolbox kit (Tocris).

    Techniques: Expressing, Derivative Assay, Staining, Immunostaining

    ( A ) Schematic representation of the small molecule screening procedure. Each well from a 96-well plate contained an individual compound from the Tocriscreen Stem cell toolbox added in the differentiation medium. ( B ) Representative images of MyHC (red) immunostaining in myotubes differentiated with selected candidates upon small molecule screening ( A ). DAPI stains blue. Scale bar is 100 μm. ( C ) Bar graph shows ratio of % MyHC-stained area to % DAPI area from hiPSC-1 myotubes differentiated with compounds candidates at 5, 10 or 20 μm relative to DMSO. Data are shown as mean of three independent replicates ± S.E.M. Statistical analyses showed no significant differences among concentrations for each compound. ( D ) Bar graphs show gene expression analysis of MYOG and MYH isoforms relative to GAPDH of hiPSC-1 myotubes differentiated with compound candidates. Data are shown as mean of three independent replicates ± S.E.M. *p<0.05 **p<0.01 ***p<0.001.

    Journal: eLife

    Article Title: Screening identifies small molecules that enhance the maturation of human pluripotent stem cell-derived myotubes

    doi: 10.7554/eLife.47970

    Figure Lengend Snippet: ( A ) Schematic representation of the small molecule screening procedure. Each well from a 96-well plate contained an individual compound from the Tocriscreen Stem cell toolbox added in the differentiation medium. ( B ) Representative images of MyHC (red) immunostaining in myotubes differentiated with selected candidates upon small molecule screening ( A ). DAPI stains blue. Scale bar is 100 μm. ( C ) Bar graph shows ratio of % MyHC-stained area to % DAPI area from hiPSC-1 myotubes differentiated with compounds candidates at 5, 10 or 20 μm relative to DMSO. Data are shown as mean of three independent replicates ± S.E.M. Statistical analyses showed no significant differences among concentrations for each compound. ( D ) Bar graphs show gene expression analysis of MYOG and MYH isoforms relative to GAPDH of hiPSC-1 myotubes differentiated with compound candidates. Data are shown as mean of three independent replicates ± S.E.M. *p<0.05 **p<0.01 ***p<0.001.

    Article Snippet: To determine whether small molecule compounds may enhance the maturation of PS cell-derived myotubes, we performed a small molecule library screening using the Tocriscreen stem cell toolbox kit (Tocris).

    Techniques: Immunostaining, Staining, Expressing

    Journal: eLife

    Article Title: Screening identifies small molecules that enhance the maturation of human pluripotent stem cell-derived myotubes

    doi: 10.7554/eLife.47970

    Figure Lengend Snippet:

    Article Snippet: To determine whether small molecule compounds may enhance the maturation of PS cell-derived myotubes, we performed a small molecule library screening using the Tocriscreen stem cell toolbox kit (Tocris).

    Techniques: Control, Recombinant, Imaging, Proliferation Assay, Sequencing

    ( A ) Bar graph shows expression profile of MYH isoforms in hiPSC-1-derived myotubes. Data are shown as mean ± S.E.M.; n = 3, ***p<0.001. ( B ) Bar graph shows the ratio of % MyHC-stained area to % DAPI area in myotubes resulting from treatment with five candidates identified by the small molecule screening. Data show significant increase (***p<0.001) compared to DMSO in all three PS cell lines analyzed (hESC-1, hiPSC-1 and hiPSC-2). Data from three independent replicates are shown, normalized to DMSO, as mean ± S.E.M. ( C ) Bar graph shows the ratio of % MyHC-stained area to % DAPI area in iPS cell-derived myotubes that had been differentiated in the presence of all candidates combined, or with individual candidates excluded from the overall combination. Data from three independent replicates are shown normalized to DMSO. Values are shown as mean ± S.E.M. ***p<0.001. ( D ) Representative images show immunostaining for MyHC (in red) in hiPSC-1 myotubes differentiated with combinatory treatments of small molecules or DMSO. DAPI stains nuclei (in blue). Scale bar is 100 μm. ( E ) Bar graph shows fusion index analysis of myotubes that were differentiated with small molecule combinations or DMSO. Data are shown as mean of three independent replicates ± S.E.M. ***p<0.001. ( F ) Stacked bar graph shows the frequency of number of nuclei per myotube upon differentiation with combinatory treatments or DMSO. Data are shown as mean of three independent replicates ± S.E.M. Statistical analysis compares each combination to DMSO. *p<0.05 **p<0.01 ***p<0.001. 10.7554/eLife.47970.006 Figure 1—source data 1. Tocriscreen Stem Cell Toolbox compounds tested during myogenic terminal differentiation of PS cell lines.

    Journal: eLife

    Article Title: Screening identifies small molecules that enhance the maturation of human pluripotent stem cell-derived myotubes

    doi: 10.7554/eLife.47970

    Figure Lengend Snippet: ( A ) Bar graph shows expression profile of MYH isoforms in hiPSC-1-derived myotubes. Data are shown as mean ± S.E.M.; n = 3, ***p<0.001. ( B ) Bar graph shows the ratio of % MyHC-stained area to % DAPI area in myotubes resulting from treatment with five candidates identified by the small molecule screening. Data show significant increase (***p<0.001) compared to DMSO in all three PS cell lines analyzed (hESC-1, hiPSC-1 and hiPSC-2). Data from three independent replicates are shown, normalized to DMSO, as mean ± S.E.M. ( C ) Bar graph shows the ratio of % MyHC-stained area to % DAPI area in iPS cell-derived myotubes that had been differentiated in the presence of all candidates combined, or with individual candidates excluded from the overall combination. Data from three independent replicates are shown normalized to DMSO. Values are shown as mean ± S.E.M. ***p<0.001. ( D ) Representative images show immunostaining for MyHC (in red) in hiPSC-1 myotubes differentiated with combinatory treatments of small molecules or DMSO. DAPI stains nuclei (in blue). Scale bar is 100 μm. ( E ) Bar graph shows fusion index analysis of myotubes that were differentiated with small molecule combinations or DMSO. Data are shown as mean of three independent replicates ± S.E.M. ***p<0.001. ( F ) Stacked bar graph shows the frequency of number of nuclei per myotube upon differentiation with combinatory treatments or DMSO. Data are shown as mean of three independent replicates ± S.E.M. Statistical analysis compares each combination to DMSO. *p<0.05 **p<0.01 ***p<0.001. 10.7554/eLife.47970.006 Figure 1—source data 1. Tocriscreen Stem Cell Toolbox compounds tested during myogenic terminal differentiation of PS cell lines.

    Article Snippet: Chemical compound, drug , Tocriscreen Stem Cell Toolbox , Tocris , Cat# 5060 , 10 µM of each compound.

    Techniques: Expressing, Derivative Assay, Staining, Immunostaining

    ( A ) Schematic representation of the small molecule screening procedure. Each well from a 96-well plate contained an individual compound from the Tocriscreen Stem cell toolbox added in the differentiation medium. ( B ) Representative images of MyHC (red) immunostaining in myotubes differentiated with selected candidates upon small molecule screening ( A ). DAPI stains blue. Scale bar is 100 μm. ( C ) Bar graph shows ratio of % MyHC-stained area to % DAPI area from hiPSC-1 myotubes differentiated with compounds candidates at 5, 10 or 20 μm relative to DMSO. Data are shown as mean of three independent replicates ± S.E.M. Statistical analyses showed no significant differences among concentrations for each compound. ( D ) Bar graphs show gene expression analysis of MYOG and MYH isoforms relative to GAPDH of hiPSC-1 myotubes differentiated with compound candidates. Data are shown as mean of three independent replicates ± S.E.M. *p<0.05 **p<0.01 ***p<0.001.

    Journal: eLife

    Article Title: Screening identifies small molecules that enhance the maturation of human pluripotent stem cell-derived myotubes

    doi: 10.7554/eLife.47970

    Figure Lengend Snippet: ( A ) Schematic representation of the small molecule screening procedure. Each well from a 96-well plate contained an individual compound from the Tocriscreen Stem cell toolbox added in the differentiation medium. ( B ) Representative images of MyHC (red) immunostaining in myotubes differentiated with selected candidates upon small molecule screening ( A ). DAPI stains blue. Scale bar is 100 μm. ( C ) Bar graph shows ratio of % MyHC-stained area to % DAPI area from hiPSC-1 myotubes differentiated with compounds candidates at 5, 10 or 20 μm relative to DMSO. Data are shown as mean of three independent replicates ± S.E.M. Statistical analyses showed no significant differences among concentrations for each compound. ( D ) Bar graphs show gene expression analysis of MYOG and MYH isoforms relative to GAPDH of hiPSC-1 myotubes differentiated with compound candidates. Data are shown as mean of three independent replicates ± S.E.M. *p<0.05 **p<0.01 ***p<0.001.

    Article Snippet: Chemical compound, drug , Tocriscreen Stem Cell Toolbox , Tocris , Cat# 5060 , 10 µM of each compound.

    Techniques: Immunostaining, Staining, Expressing

    Journal: eLife

    Article Title: Screening identifies small molecules that enhance the maturation of human pluripotent stem cell-derived myotubes

    doi: 10.7554/eLife.47970

    Figure Lengend Snippet:

    Article Snippet: Chemical compound, drug , Tocriscreen Stem Cell Toolbox , Tocris , Cat# 5060 , 10 µM of each compound.

    Techniques: Control, Recombinant, Imaging, Proliferation Assay, Sequencing